Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: Facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging

Theranostics

Volumn 3, Issue 3, 2013, Pages 181-189

  Liu, Shuanglong ^a   Lin, Tzu Pin ^b   Li, Dan ^a,c   Leamer, Lauren ^b   Shan, Hong ^c   Li, Zibo ^a   Gabbaï, François P ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

18F 19F exchange; BODIPY; Dual modality; Fluorsence; PET

Indexed keywords

1,3,5,7 TETRAMETHYL 8 [4 (N,N DIMETHYLAMINO)PHENYL] 4,4 DIFLUORO 4 BORA 3A,4A DIAZA INDACENE; ARGINYLGLYCYLASPARTIC ACID; FLUORINE; FLUORINE 18; LEWIS ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4,4 DIFLUORO 4 BORA 3A,4A DIAZA S INDACENE; 4,4-DIFLUORO-4-BORA-3A,4A-DIAZA-S-INDACENE; BORON DERIVATIVE; DIAGNOSTIC AGENT; FLUORESCENT DYE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VIVO STUDY; ISOTOPE ANALYSIS; ISOTOPE LABELING; MOLECULAR PROBE; MOUSE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; REVIEW; TUMOR DIAGNOSIS; TUMOR XENOGRAFT; 18F-19F EXCHANGE.; ARTICLE; BODIPY; CHEMISTRY; DUAL MODALITY; FLUORSENCE; HUMAN; METHODOLOGY; PET; RADIOGRAPHY;

18F-19F EXCHANGE.; BODIPY; DUAL MODALITY; FLUORSENCE; PET;

BORON COMPOUNDS; DIAGNOSTIC IMAGING; FLUORESCENT DYES; FLUORINE RADIOISOTOPES; HUMANS; LEWIS ACIDS; NEOPLASMS; OPTICAL IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878809478     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5984     Document Type: Review

References (44)

1. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology. 2007; 245: 333-56.
2. Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics. 2012; 2: 437-47.
3. Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics. 2012; 2: 424-6.
4. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007; 244: 39-47.
5. Loudet A, Burgess K. BODIPY dyes and their derivatives: Syntheses and spectroscopic properties. Chem Rev. 2007; 107: 4891-932.
6. Ulrich G, Ziessel R, Harriman A. The chemistry of fluorescent Bodipy dyes: versatility unsurpassed. Angew Chem Int Ed. 2008; 47: 1184-201.
7. 18F-labeling of marimastat, a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases. Med Chem Comm. 2011; 2: 942-9.
8. 18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer. Cancer Res. 2010; 70: 7562-9.
9. 19F]-labeled aryltrifluoroborates with high kinetic stability. Tetrahedron Lett. 2008; 49: 3152-6.
10. 18F]-labeled aryltrifluoroborate. J Fluorine Chem. 2008; 129: 349-58.
11. 18F-Labeling. J Am Chem Soc. 2005; 127: 13094-5.
12. 18F-Labeled Aryltrifluoroborates for Use in PET Imaging. J Org Chem. 2008; 73: 4662-70.
13. 18F]-Labeled Aryltrifluoroborate Radiotracers: In Vivo Positron Emission Tomography Imaging of Stable Aryltrifluoroborate Clearance in Mice. J Am Chem Soc. 2008; 130: 12045-55.
14. Smith GE, Sladen HL, Biagini SCG, Blower PJ. Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with Positron Emission Tomography. Dalton Trans. 2011; 40: 6196-205.
15. 18F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010; 37: 2108-16.
16. 18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Commun. 2011; 32: 98-105.
17. 18F Labeling of a Near-Infrared Fluorophore Enables Positron Emission Tomography and Optical Imaging of Sentinel Lymph Nodes. Bioconjug Chem. 2010; 21: 1811-9.
18. Hudnall TW, Lin T-P, Gabbaï FP. Substitution of hydroxide by fluoride at the boron center of a BODIPY dye. J Fluorine Chem. 2010; 131: 1182-6.
19. Hudnall TW, Gabbaï FP. A BODIPY boronium cation for the sensing of fluoride ions. Chem Commun. 2008;: 4596-7.
20. 18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun. 2011; 47: 9324-6.
21. 18F]BODIPY: Bifunctional Reporter for Hybrid Optical/Positron Emission Tomography Imaging. Angew Chem Int Ed. 2012; 51: 6813.
22. 18F]BODIPY: Bifunctional Reporter for Hybrid Optical/Positron Emission Tomography Imaging. Angew Chem Int Ed. 2012; 51: 4603-6.
23. Purser S, Moore PR, Swallow S, Gouverneur V. Fluorine in medicinal chemistry. Chem Soc Rev. 2008; 37: 320-30.
24. Miller PW, Long NJ, Vilar R, Gee AD. Synthesis of C-11, F-18, O-15, and N-13 Radiolabels for Positron Emission Tomography. Angew Chem Int Ed. 2008; 47: 8998-9033.
25. Dolle F, Roeda D, Kuhnast B, Lasne M-C. Fluorine-18 chemistry for molecular imaging with positron emission tomography. In: Tressaud A, editor. Fluorine and Health: Elsevier, Amsterdam; 2008;:3-65.
26. Smith TAD. F-18 Fluoride labelling of macromolecules in aqueous conditions: silicon and boroaryl-based F-18 fluorine acceptors, F-18 FDG conjugation and (AlF)-F-18 chelation. J Labelled Compd Radiopharm. 2012; 55: 281-8.
27. Gu YH, Huang D, Liu ZG, Huang JG, Zeng WB. Labeling Strategies with F-18 for Positron Emission Tomography Imaging. Med Chem. 2011; 7: 334-44.
28. Olberg DE, Hjelstuen OK. Labeling Strategies of Peptides with F-18 for Positron Emission Tomography. Curr Top Med Chem. 2010; 10: 1669-79.
29. Li ZB, Conti PS. Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliver Rev. 2010; 62: 1031-51.
30. Hooker JM. Modular strategies for PET imaging agents. Curr Opin Chem Biol. 2010; 14: 105-11.
31. Bonnier C, Piers WE, Parvez M, Sorensen TS. Borenium cations derived from BODIPY dyes. Chem Commun. 2008;: 4593-5.
32. Hoogendoorn S, Blom AE, Willems LI, van der Marel GA, Overkleeft HS. Synthesis of pH-activatable red fluorescent BODIPY dyes with distinct functionalities. Org Lett. 2011; 13: 5656-9.
33. Huang CW, Li Z, Cai H, Shahinian T, Conti PS. Biological stability evaluation of the alpha2beta1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem. 2011; 22: 256-63.
34. 18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun (Camb). 2011; 47: 9324-6.
35. 19F isotopic exchange: Radiofluorination of zwitterionic aryltrifluoroborates and in vivo stability studies. Med Chem Comm. 2012; 3: 1305-8.
36. Gutmann VHT. The solvent benzoyl chloride. I. The formation of anhydrous chlorides and their behavior in benzoyl chloride. Monatsh Chem. 1957; 88: 216-27.
37. 18F Radiolabeling for PET. J Nucl Med. 2009; 50: 991-8.
38. McBride WJ, D'Souza CA, Karacay H, Sharkey RM, Goldenberg DM. New Lyophilized Kit for Rapid Radiofluorination of Peptides. Bioconjug Chem. 2012; 23: 538-47.
39. 18F-FPRGD4). J Nucl Med. 2007; 48: 1536-44.
40. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor avß3 integrin expression. J Nucl Med. 2007; 48: 1162-71.
41. Xiong J-P, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal Structure of the Extracellular Segment of Integrin avß3 in Complex with an Arg-Gly-Asp Ligand. Science. 2002; 296: 151-5.
42. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET Imaging of Integrin avß3 Expression. Theranostics. 2011; 1: 48-57.
43. Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011; 1: 189-200.
44. Morrison M, Cuthbertson A. Integrin imaging to evaluate treatment response. Theranostics. 2011; 1: 149-53